Research programme: miRNA therapeutics - Synlogic

Drug Profile

Research programme: miRNA therapeutics - Synlogic

Alternative Names: let-7; let-7 mimic; let-7b; let-7c; let-7g; miR-101; miR-192; miR-215; miR-Rx01; miR-Rx02; miR-Rx03; miR-Rx04; miR-Rx05; miR-Rx06; miR-Rx07; miR-Rx16; miR-Rx16 mimic; miR-Rxlet-7; Tumour suppressor microRNAs - Synlogic

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asuragen
  • Developer Mirna Therapeutics; Synlogic; University of Texas M. D. Anderson Cancer Center
  • Class MicroRNAs
  • Mechanism of Action Oncogene protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Gastric cancer; Ovarian cancer
  • No development reported Colorectal cancer; Haematological malignancies; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top